Javier Cortes Castan, Oncólogo clínico

DR. JAVIER CORTÉS CASTÁN, MD, PhD Medical Oncologist | Director & Founder, International Breast Cancer Center (IBCC) Centro Médico Teknon — Quironsalud Group · Barcelona, Spain

KEY FIGURES 550+ International Publications · 800+ Conference Presentations · 12 Treatments Approved in Europe · 150+ Active Clinical Trials

PROFESSIONAL PROFILE

Dr. Javier Cortés Castán is one of the world's foremost authorities in breast cancer treatment and research. As Founder and Director of the International Breast Cancer Center (IBCC) at Centro Médico Teknon (Quironsalud Group) in Barcelona, he has spent over 25 years advancing the global standard of care for HER2-positive and triple-negative breast cancer — the two most complex and aggressive subtypes.

Ranked #1 globally in HER2+ breast cancer expertise (Expertscape), Dr. Cortés has led landmark clinical trials resulting in 12 new metastatic breast cancer treatment approvals in Europe. He is the only Spanish oncologist with two articles in CA: A Cancer Journal for Clinicians — the world's highest-impact oncology journal — and the 2026 Giants of Cancer Care® honoree (OncLive), being the only non-American specialist named in this year's cohort of 14 global pioneers.

ACADEMIC BACKGROUND

• MD, Medicine and Surgery — Universidad Autónoma de Madrid (1996)
• PhD, Medical Oncology — University of Navarra (2002) · Summa Cum Laude

PROFESSIONAL EXPERIENCE — 25+ Years of International Excellence

◆ Director & Founder, International Breast Cancer Center (IBCC) — CURRENT Centro Médico Teknon, Quironsalud Group · Barcelona, Spain (2019 – present)

• Leads one of Europe's premier breast cancer centers, providing cutting-edge diagnosis and treatment for patients from 40+ countries
• Directs 150+ active clinical research projects, focusing on HER2+ and triple-negative subtypes

◆ Scientific Director, IOB Madrid — CURRENT Fundación Hospitalarias Madrid · Madrid, Spain

◆ Co-Founder, MedSIR (Medica Scientia Innovation Research) — CURRENT International clinical research organization specializing in breast cancer trial design and management

◆ Head, Breast Cancer & Gynecological Tumors Unit Hospital Ramón y Cajal · Madrid, Spain · 2015–2019

◆ Head, Breast Cancer Unit Hospital Vall d'Hebron · Barcelona, Spain · 2006–2015

AREAS OF EXPERTISE

▼ HER2-Positive Breast Cancer

• Targeted therapy (trastuzumab, pertuzumab, T-DM1, T-DXd/trastuzumab deruxtecan)
• HER2-low breast cancer — emerging treatment paradigm
• Management of HER2+ metastatic and early-stage disease

▼ Triple-Negative Breast Cancer (TNBC)

• Immunotherapy combinations (pembrolizumab, atezolizumab)
• PARP inhibitors for BRCA-mutated TNBC
• Antibody-drug conjugates (sacituzumab govitecan)
• Neoadjuvant and adjuvant strategies for early TNBC

▼ Hormone Receptor-Positive / Luminal Breast Cancer

• CDK4/6 inhibitors combined with endocrine therapy
• PI3K pathway inhibitors; everolimus-based regimens

▼ Metastatic Breast Cancer Management

• Comprehensive multidisciplinary approach to advanced disease
• Precision medicine and biomarker-driven treatment selection
• Clinical trial access for patients with refractory disease

LANDMARK CLINICAL TRIALS

KEYNOTE-522 Pembrolizumab (immunotherapy) + chemotherapy for early-stage triple-negative breast cancer. → Established new global standard of care for TNBC

KEYNOTE-355 Pembrolizumab for PD-L1+ metastatic triple-negative breast cancer. → Led to first immunotherapy approval for TNBC in Europe

DESTINY-Breast03 Trastuzumab deruxtecan (T-DXd) vs. T-DM1 in HER2-positive metastatic breast cancer. → Redefined the global second-line HER2+ treatment paradigm

Dr. Cortés's research leadership has directly contributed to 12 new metastatic breast cancer treatment approvals in Europe over the past decade. He currently leads or co-leads more than 150 active clinical and translational research projects.

AWARDS & INTERNATIONAL RECOGNITION

2026 — Giants of Cancer Care® — Breast Cancer Category OncLive · Only non-American specialist honored among 14 global oncology pioneers in the 2026 cohort

2025 — Top 10 Best Oncologists in Spain MERCO / Monitor de Reputación Sanitaria (MRS)

2024 — European Award in Medicine Siglo XXI — Medical Oncology Category European Medical Awards · Barcelona, Spain

2020 — Premio Nacional de Medicina Siglo XXI Spanish National Medicine Award

#1 World Expert in HER2+ Breast Cancer (Expertscape Global Rankings) #4 World Expert in Breast Cancer Overall (Expertscape Global Rankings)

RESEARCH & PUBLICATIONS

• 550+ peer-reviewed scientific publications, primarily on breast cancer biology and treatment
• 800+ invited presentations at international conferences (ESMO, ASCO, AACR, SABCS)
• 150+ ongoing clinical and translational research projects
• Peer reviewer for: NEJM, The Lancet, Lancet Oncology, Annals of Oncology, JCO, JAMA Oncology

Unique distinction: The only Spanish oncologist with two articles published in CA: A Cancer Journal for Clinicians — the world's highest-impact cancer journal (Impact Factor >500).

PROFESSIONAL MEMBERSHIPS & LEADERSHIP ROLES

• ESMO (European Society for Medical Oncology) — Member of the Scientific Committee
• Breast Cancer Section Chair, ESMO Annual Congress 2020
• Co-Chair, Breast Cancer Section, AACR Annual Meeting 2020
• Co-Chair, Immunotherapy Section, AACR Annual Meeting 2021
• SEOM (Spanish Society of Medical Oncology) — Member
• ASCO (American Society of Clinical Oncology) — Member
• AACR (American Association for Cancer Research) — Member

LANGUAGES

• Spanish — Native
• English — Fluent (all consultations available in English)
• Translation available upon request (Russian, Ukrainian, and others through Bookimed)

WHY CHOOSE DR. JAVIER CORTÉS CASTÁN?

• World's #1 expert in HER2+ breast cancer (Expertscape) with 25+ years of specialized oncology experience
• Direct access to the most advanced approved treatments AND early-phase clinical trials not available elsewhere
• Led the trials that created today's global treatment standards — your doctor is the researcher who designed the protocols now used worldwide
• 550+ publications and 12 new European treatment approvals resulting from his research
• Part of Centro Médico Teknon, one of Spain's most advanced hospitals — JCI-accredited and a flagship center of Quironsalud, Europe's largest hospital group
• International patient experience: routine care for patients from Russia, Ukraine, the UK, the Middle East, Latin America, and beyond